{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-067378","form_type":"8-K","ticker":"ATNM","cik":"0001388320","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2022-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.407290+00:00","generated_at":"2026-06-22T21:29:36.887627+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Actinium's Iomab-B meets primary endpoint in Phase 3 SIERRA AML trial (p<0.0001)","bullets":["Phase 3 SIERRA trial of Iomab-B in AML patients 55+ with active relapsed/refractory disease met primary endpoint of durable complete remission (dCR) at 6 months with p<0.0001.","Iomab-B is a targeted radiotherapy conditioning regimen prior to bone marrow transplant; compared to conventional care with intent to transplant.","Company to submit Biologics License Application (BLA) to FDA for approval of Iomab-B; additional SIERRA data expected by year-end 2022.","CEO Sandesh Seth calls it a significant milestone; CMO Avinash Desai highlights statistical significance and increased access to BMT."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-067378","json":"https://secwatch.observer/filing/0001213900-22-067378.json","markdown":"https://secwatch.observer/filing/0001213900-22-067378.md","text":"https://secwatch.observer/filing/0001213900-22-067378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022067378/0001213900-22-067378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390022067378/ea167769-8k_actinium.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T21:29:36.887627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}